ISSN 2412-4036 (print)
ISSN 2713-1823 (online)

Azithromycin in asthma: Anti-inflammatory and immunomodulatory mechanisms and therapeutic potential

L.Z. Bolieva

North Ossetian State Medical Academy, Vladikavkaz, Russian Federation

Список литературы

  1. Clinical guidelines. Bronchial asthma. Russian Association of Allergists and Clinical Immunologists, Union of Pediatricians of Russia, Association of Doctors and Specialists in Occupational Medicine, Russian Respiratory Society. Rubricator of clinical gudelines of the Ministry of Healthcare of Russia. 2024. ID: 359_3. URL: https://cr.minzdrav.gov.ru/view-cr/359_3 (date of access – 10.09.2026) (In Russ.)].
  2. Global Strategy for Asthma Management and Prevention (2026 update). URL: https://ginasthma.org/ (date of access – 10.09.202610.09.2026)
  3. Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): A randomized, double-blind, placebo-controlled trial. Lancet. 2017;390(10095):659–68.

    PMID: 28687413. https://doi.org/10.1016/S0140-6736(17)31281-3

  4. Ologundudu LM, Wong MM, Islam N, Rayner DG, Chu AWL, Loeb M, et al. Macrolides for asthma: A systematic review and meta-analysis of randomized trials. J Allergy Clin Immunol. 2026;158(4):970–81.

    PMID: 41654262. https://doi.org/10.1016/j.jaci.2026.01.024

  5. Sadeghdoust M, Mirsadraee M, Aligolighasemabadi F, Khakzad MR, Hashemi Attar A, Naghibi S. Effect of azithromycin on bronchial wall thickness in severe persistent asthma: A double-blind placebo-controlled randomized clinical trial. Respir Med. 2021;185:106494.

    PMID: 34116330. https://doi.org/10.1016/J.RMED.2021.106494

  6. Heidary M, Ebrahimi Samangani A, Kargari A, Kiani Nejad A, Yashmi I, Motahar M, et al. Mechanism of action, resistance, synergism, and clinical implications of azithromycin. J Clin Lab Anal. 2022;36(6):e24427.

    PMID: 35447019. PMCID: PMC9169196. https://doi.org/10.1002/jcla.24427

  7. Petrov VI, Sychev DA, Khokhlov AL, Ardentova NN, Afanasiev VV, Babak SV, et al. Clinical pharmacology: National guidelines. Monograph. 2nd edition, revised and added. Moscow: GEOTAR-Media. 2024; 816 pp. (In Russ.)].

    EDN: KBVMXL. ISBN: 978-5-9704-8266-7.

  8. Kudoh S, Uetake T, Hagiwara K, Hirayama M, Hus LH, Kimura H, Sugiyama Y. [Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis]. Nihon Kyobu Shikkan Gakkai Zasshi. 1987;25(6):632–42 (In Japanese). PMID: 3682440.
  9. Fujii T, Kadota J, Kawakami K, Iida K, Shirai R, Kaseda M, et al. Long-term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Thorax. 1995;50(12):1246–52.

    PMID: 8553295. PMCID: PMC1021345. https://doi.org/10.1136/thx.50.12.1246

  10. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med. 1998;157(6 Pt 1):1829–32.

    PMID: 9620913. https://doi.org/10.1164/ajrccm.157.6.9710075

  11. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics – part 1: Biological mechanisms. Respiration. 2011;81(1):67–74.

    PMID: 20733281. https://doi.org/10.1159/000320319

  12. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics – part 2: Advantages and disadvantages of long-term, low-dose macrolide therapy. Respiration. 2011;81(1):75–87.

    PMID: 20733282. https://doi.org/10.1159/000320320

  13. Zimmermann P, Ziesenitz VC, Curtis N, Ritz N. The immunomodulatory effects of macrolides – a systematic review of the underlying mechanisms. Front Immunol. 2018;9:302.

    PMID: 29593707. PMCID: PMC5859047. https://doi.org/10.3389/FIMMU.2018.00302

  14. Culic O, Erakovic V, Cepelak I, Barisic K, Brajsa K, Ferencic Z, et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol. 2002;450(3):277–89.

    PMID: 12208321. https://doi.org/10.1016/s0014-2999(02)02042-3

  15. Murphy BS, Sundareshan V, Cory TJ, Hayes D Jr, Anstead MI, Feola DJ. Azithromycin alters macrophage phenotype. J Antimicrob Chemother. 2008;61(3):554–60.

    PMID: 18230686. https://doi.org/10.1093/jac/dkn007

  16. Wang J, Xie L, Wang S, Lin J, Liang J, Xu J. Azithromycin promotes alternatively activated macrophage phenotype in systemic lupus erythematosus via PI3K/Akt signaling pathway. Cell Death Dis. 2018;9(11):1080.

    PMID: 30348950. PMCID: PMC6197274. https://doi.org/10.1038/s41419-018-1097-5

  17. Zhang B, Kopper TJ, Liu X, Cui Z, Van Lanen SG, Gensel JC. Macrolide derivatives reduce proinflammatory macrophage activation and macrophage-mediated neurotoxicity. CNS Neurosci Ther. 2019;25(5):591–600.

    PMID: 30677254. PMCID: PMC6488883. https://doi.org/10.1111/cns.13092

  18. Hodge S, Hodge G, Brozyna S, Jersmann H, Holmes M, Reynolds PN. Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages. Eur Respir J. 2006;28(3):486–95.

    PMID: 16737992. https://doi.org/10.1183/09031936.06.00001506

  19. Persson HL, Vainikka LK, Sege M, Wennerstrom U, Dam-Larsen S, Persson J. Leaky lysosomes in lung transplant macrophages: Azithromycin prevents oxidative damage. Respir Res. 2012;13(1):83.

    PMID: 23006592. PMCID: PMC3511206. https://doi.org/10.1186/1465-9921-13-83

  20. Song Y, Fu W, Zhang Y, Huang D, Wu J, Tong S, et al. Azithromycin ameliorated cigarette smoke-induced airway epithelial barrier dysfunction by activating Nrf2/GCL/GSH signaling pathway. Respir Res. 2023;24(1):69.

    PMID: 36879222. PMCID: PMC9990325. https://doi.org/10.1186/s12931-023-02375-9

  21. Hassanein EHM, Sayed GA, Alzoghaibi AM, Alammar AS, Abdel-Wahab BA, Abd El-Ghafar OAM, et al. Azithromycin mitigates cisplatin-induced lung oxidative stress, inflammation and necroptosis by upregulating SIRT1, PPARγ, and Nrf2/HO-1 signaling. Pharmaceuticals (Basel). 2022;16(1):52.

    PMID: 36678549. PMCID: PMC9861532. https://doi.org/10.3390/ph16010052

  22. Bystrzycka W, Manda-Handzlik A, Sieczkowska S, Moskalik A, Demkow U, Ciepiela O. Azithromycin and chloramphenicol diminish neutrophil extracellular traps (NETs) release. Int J Mol Sci. 2017;18(12):2666.

    PMID: 29292737. PMCID: PMC5751268. https://doi.org/10.3390/ijms18122666

  23. Aoshiba A, Nagai A, Konno K. Erythromycin shortens neutrophil survival by accelerating apoptosis. Antimicrob Agents Chemother. 1995;39(4):872–77.

    PMID: 7785987. PMCID: PMC162645. https://doi.org/10.1128/AAC.39.4.872. Erratum in: Antimicrob Agents Chemother 1997;41(8):1847.

  24. Porto B, Stein RT. Neutrophil extracellular traps in pulmonary diseases: Too much of a good thing? Front Immunol. 2016;7:311.

    PMID: 27574522. PMCID: PMC4983612. https://doi.org/10.3389/fimmu.2016.00311

  25. Abdelghaffar H, Vazifeh D, Labro MT. Comparison of various macrolides on stimulation of human neutrophil degranulation in vitro. J Antimicrob Chemother. 1996;38(1):81–93.

    PMID: 8858460. https://doi.org/10.1093/jac/38.1.81

  26. Schultz MJ, Speelman P, Hack CE, Buurman WA, van Deventer SJ, van Der Poll T. Intravenous infusion of erythromycin inhibits CXC chemokine production, but augments neutrophil degranulation in whole blood stimulated with, Streptococcus pneumoniae. J Antimicrob Chemother. 2000;46(2):235–40.

    PMID: 10933646. https://doi.org/10.1093/jac/46.2.235

  27. Iwamoto S, Kumamoto T, Azuma E, Hirayama M, Ito M, Amano K, et al. The effect of azithromycin on the maturation and function of murine bone marrow-derived dendritic cells. Clin Exp Immunol. 2011;166(3):385–92.

    PMID: 22059997. PMCID: PMC3232387. https://doi.org/10.1111/j.1365-2249.2011.04480.x

  28. Polancec DS, Munic Kos V, Banjanac M, Vrancic M, Cuzic S, Belamaric D, et al. Azithromycin drives in vitro GM-CSF/IL-4-induced differentiation of human blood monocytes toward dendritic-like cells with regulatory properties. J Leukoc Biol. 2011;91(2):229–43.

    PMID: 22131344. https://doi.org/10.1189/jlb.1210655

  29. Sugiyama K, Shirai R, Mukae H, Ishimoto H, Nagata T, Sakamoto N, et al. Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells. Clin Exp Immunol. 2007;147(3):540–46.

    PMID: 17302905. PMCID: PMC1810497. https://doi.org/10.1111/j.1365-2249.2007.03299.x

  30. Lin SJ, Kuo ML, Hsiao HS, Le PT. Azithromycin modulates immune response of human monocyte-derived dendritic cells and CD4+ T cells. Int Immunopharmacol. 2016;40:318–26.

    PMID: 27664570. https://doi.org/10.1016/j.intimp.2016.09.012

  31. Ishida Y, Abe Y, Harabuchi Y. Effects of macrolides on antigen presentation and cytokine production by dendritic cells and T lymphocytes. Int J Paediatr Otorhinolaryngol. 2007;71(2):297–305.

    PMID: 17137638. https://doi.org/10.1016/j.ijporl.2006.10.016

  32. Kadota J, Mizunoe S, Kishi K, Tokimatsu I, Nagai H, Nasu M. Antibiotic-induced apoptosis in human activated peripheral lymphocytes. Int J Antimicrob Agents. 2005;25(3):216–20.

    PMID: 15737515. https://doi.org/10.1016/j.ijantimicag.2004.10.009

  33. Weng D, Wu Q, Chen XQ, Du YK, Chen T, Li H, et al. Azithromycin treats diffuse panbronchiolitis by targeting T cells via inhibition of mTOR pathway. Biomed Pharmacother. 2019;110:440–48.

    PMID: 30530046. https://doi.org/10.1016/j.biopha.2018.11.090

  34. Ratzinger F, Haslacher H, Poeppl W, Hoermann G, Kovarik JJ, Jutz S, et al. Azithromycin suppresses CD4+ T-cell activation by direct modulation of mTOR activity. Sci Rep. 2014;4:7438.

    PMID: 25500904. PMCID: PMC4262884. https://doi.org/10.1038/srep07438

  35. Kawakami K, Kadota J, Iida K, Fujii T, Shirai R, Matsubara Y, Kohno S. Phenotypic characterization of T cells in bronchoalveolar lavage fluid (BALF) and peripheral blood of patients with diffuse panbronchiolitis; the importance of cytotoxic T cells. Clin Exp Immunol. 1997;107(2):410–16.

    PMID: 9030883. PMCID: PMC1904572. https://doi.org/10.1111/j.1365-2249.1997.259-ce1139.x

  36. Vandermeulen E, Somers J, Bellon H, Verleden SE. A mechanistic study on the effect of azithromycin on T-helper-17 cells. Eur Respir J. 2015;46(Suppl 59):OA3275.

    https://doi.org/10.1183/13993003.congress-2015.OA3275

  37. Clinical guidelines. Chronic obstructive pulmonary disease. Russian Respiratory Society, Russian Scientific Medical Society of Internal Medicine, Association of Doctors and Occupational Medicine Specialists. Rubricator of clinical gudelines of the Ministry of Healthcare of Russia. 2024. ID: 603_3. (In Russ.) https://cr.minzdrav.gov.ru/view-cr/603_3 (date of access – 10.09.2026) (In Russ.)].
  38. Menzies-Gow A, Bafadhel M, Busse WW, Casale TB, Kocks JWH, Pavord ID, et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol. 2020;145(3):757–65.

    PMID: 31866436. https://doi.org/10.1016/j.jaci.2019.12.006

  39. Lommatzsch M, Buhl R, Canonica GW, Ribas CD, Nagase H, Brusselle GG, et al. Pioneering a paradigm shift in asthma management: Remission as a treatment goal. Lancet Respir Med. 2024;12(2):96–99.

    PMID: 38071999. https://doi.org/10.1016/s2213-2600(23)00415-0

  40. Hiles SA, McDonald VM, Guilhermino M, Brusselle GG, Gibson PG. Does maintenance azithromycin reduce asthma exacerbations? An individual participant data meta-analysis. Eur Respir J. 2019;54(5):1901381.

    PMID: 31515407. https://doi.org/10.1183/13993003.01381-2019

  41. Hahn DL, Plane MB, Mahdi OS, Byrne GI. Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clin Trials. 2006;1(2):e11.

    PMID: 16871333. PMCID: PMC1488900. https://doi.org/10.1371/journal.pctr.0010011

  42. He J, Zhu N, Chen XD. Clinical impacts of azithromycin on lung function and cytokines for asthmatic patients. Fudan University J Med Sci. 2009;36(6):719–22.
  43. Hahn DL, Grasmick M, Hetzel S, Yale S; AZMATICS (AZithroMycin-Asthma Trial In Community Settings) Study Group. Azithromycin for bronchial asthma in adults: An effectiveness trial. J Am Board Fam Med. 2012;25(4):442–59.

    PMID: 22773713. https://doi.org/10.3122/jabfm.2012.04.110309

  44. Cameron EJ, Chaudhuri R, Mair F, McSharry C, Greenlaw N, Weir CJ, et al. Randomised controlled trial of azithromycin in smokers with asthma. Eur Respir J. 2013;42(5):1412–15.

    PMID: 24036246. PMCID: PMC3814414. https://doi.org/10.1183/09031936.00093913

  45. Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): A multicentre randomised double-blind placebo-controlled trial. Thorax. 2013;68(4):322e9.

    PMID: 23291349. https://doi.org/10.1136/thoraxjnl-2012-202698

  46. Juniper EF, Svensson K, Mork AC, Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med. 2005;99(5):553–58.

    PMID: 15823451. https://doi.org/10.1016/j.rmed.2004.10.008

  47. O’Neill C, Gibson PG, Heaney LG, Upham JW, Yang IA, Reynolds PN, et al. The cost-effectiveness of azithromycin in reducing exacerbations in uncontrolled asthma. Eur Resp J. 2021;57(2):2002436.

    PMID: 33008933. https://doi.org/10.1183/13993003.02436-2020